Morgan Freeman is the latest actor unhappy with AI trying to mimic his voice without his permission.
In a conversation with The Guardian, published Monday, the actor explained that he was “PO’d” about the surge of AI creating…
Author: admin
-
Global energy body’s fossil fuel backpedal – Politico
- Global energy body’s fossil fuel backpedal Politico
- World Energy Outlook 2025 – Analysis IEA – International Energy Agency
- Supply boom in cheaper renewables will seal end of fossil fuel era, says IEA The Guardian
- World oil and gas demand could grow until 2050, IEA says Reuters
- Economic and demographic trends to create opportunities for solar as world becomes ‘thirsty for energy’ PV Tech
Continue Reading
-
Nikkei 225, Hang Seng Index
View of the Skytree from Ueno and Asakusa in Tokyo
Jackal Pan | Moment | Getty Images
Asia-Pacific markets mostly rose Thursday, following mixed trading on Wall Street as investors kept an eye on the U.S. government, which appeared poised to reopen as soon as the end of the week.
Japan’s benchmark Nikkei 225 index rose 0.23% in early trading, while the Topix added 0.62% to hit a record high.
South Korea’s Kospi rose 1.07%, while the small-cap Kosdaq jumped 2.52%.
Australia’s S&P/ASX 200 was down 0.25%.
Futures for Hong Kong’s Hang Seng Index pointed to a lower open, trading at 26,899, against the index’s previous close of 26,922.73.
U.S. equity futures ticked lower in early Asian hours after a continued market rotation powered the Dow Jones Industrial Average to record its first close above 48,000 Wednesday stateside.
Overnight, the 30-stock Dow closed up 326.86 points, or 0.68%, at 48,254.82. The index also hit a fresh all-time intraday high in the session. The S&P 500 traded around the flatline, settling up 0.06% at 6,850.92, while the Nasdaq Composite dropped 0.26% to finish at 23,406.46.
— CNBC’s Sean Conlon and Pia Singh contributed to this report.
Continue Reading
-
Live updates from a 12-game night in the NBA
Jalen Brunson and the New York Knicks host the Orlando Magic in the opening game of our ESPN doubleheader at 7 ET.
Enjoy the best of Wednesday’s slate with the NBA.com live blog, featuring all of the meaningful moments, performances,…
Continue Reading
-
The next macOS update can turn your screen into a ring light
Sometimes, the best features in a new operating system aren’t the flashy ones that get broadcast during a keynote. They’re subtle improvements that naturally fit into how you use your device and just make the experience better. One of those…
Continue Reading
-
Switching APOE4 to APOE2 in adult mice reduces Alzheimer’s pathology and improves memory
By flipping a single genetic switch from APOE4 to APOE2 in adult mice, researchers reversed key Alzheimer’s-like changes in the brain while revealing the metabolic trade-offs that future APOE-targeted therapies must safely…
Continue Reading
-
Alzheimer’s Risk Predicted Years Before Symptoms Appear – Inside Precision Medicine
- Alzheimer’s Risk Predicted Years Before Symptoms Appear Inside Precision Medicine
- Podcast: The Science of Detecting Alzheimer’s Disease Decades Earlier University of Miami
- New diagnostic approach identifies dementia stages based on…
Continue Reading
-
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development USA – English APAC – English APAC – Traditional Chinese
– Using Ascletis’ proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human primate studies.
– ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study.
– Co-formulation of ASC36 and ASC35 demonstrated approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in a head-to-head DIO rat study.
– Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH.
– Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for co-formulation of ASC36 and ASC35 is expected in the second quarter of 2026.
– The Company will host a conference call in Mandarin at 10:00 a.m. China Standard Time on November 13, 2025.
HONG KONG, Nov. 12, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces the co-formulation of ASC36, a once-monthly next-generation amylin receptor agonist and ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for co-formulation of ASC36 and ASC35 for the treatment of obesity in the second quarter of 2026.
Both ASC36, a once-monthly next-generation amylin receptor agonist, and ASC35, a once-monthly next-generation GLP-1R/GIPR dual agonist, were discovered and developed in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. Ascletis has successfully co-formulated ASC36 and ASC35 in the proprietary ultra-long-acting formulation to enable once monthly subcutaneous (SQ) administration using its ULAP technology. Co-formulation of ASC36 and ASC35 had excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH. Some of amylin receptor peptide agonists aggregate or precipitate at neutral pH, which leads to loss of potency, turbidity/particles, device clogging, and higher immunogenicity risk.
In head-to-head non-human primate (NHP) studies, co-formulation of ASC36 and ASC35 demonstrated a comparable pharmacokinetic profile to ASC36 and ASC35 dosed alone, supporting once-monthly SQ dosing.
ASC36 monotherapy demonstrated approximately 32% greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study. ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study (press release). The co-formulation of ASC36 and ASC35 demonstrated approximately 51% greater relative body weight reduction compared to the co-formulation of eloralintide and tirzepatide in a head-to-head DIO rat study (Table 1).
Table 1. ASC36 monotherapy and co-formulation of ASC36 and ASC35 demonstrated statistically and significantly more weight loss than eloralintide monotherapy and the co-formulation of eloralintide and tirzepatide in DIO rats after 7-day treatment
Group
Dosing
Total body weight change
from baselineGreater relative weight
loss versus eloralintide
monotherapy or co-
formulation of eloralintide
and tirzepatideObese rats treated
with vehicleVehicle,
SQ, Q2D
-0.5 %
–
Obese rats treated
with ASC36
monotherapy5 nmol/kg,
SQ, Q2D
-9.6%
(p =0.028 vs eloralintide
monotherapy)32%
(vs eloralintide
monotherapy)Obese rats treated
with eloralintide
monotherapy5 nmol/kg,
SQ, Q2D
-7.3 %
–
Obese rats treated
with co-formulation
of ASC36 and
ASC355 nmol/kg
ASC36/8
nmol/kg ASC35,SQ, Q2D
-14.5%
(p <0.0001 vs eloralintide
monotherapy; p <0.0001
vs co-formulation of
eloralintide and
tirzepatide)99%
(vs eloralintide
monotherapy)51%
(vs co-formulation of
eloralintide and
tirzepatide)Obese rats treated
with co-formulation
of eloralintide and
tirzepatide5 nmol/kg
eloralintide/8
nmol/kg
tirzepatide,SQ, Q2D
-9.6 %
–
Note: DIO rats/obese rats: diet-induced obese rats; SQ: subcutaneous; Q2D: once every two days.
“Based on these encouraging preclinical data, we believe the co-formulation of ASC36 and ASC35 has the potential to lead to greater weight loss reduction in people with obesity than single-agent therapies can achieve alone,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “The growing body of evidence reinforces our platform technologies’ ability to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides.”
Monotherapy and Co-formulation Therapies with ASC36
Ascletis is developing ASC36 as the cornerstone of its once-monthly therapies for the treatment of cardio-metabolic diseases including obesity. With the potential for better efficacy and improved tolerability to GLP-1 therapies, ASC36 is an ideal drug candidate to develop as a monotherapy and co-formulations with other long-acting agents such as ASC35 and potentially ASC47, an adipose-targeted thyroid hormone receptor beta (THRβ) agonist.
Ascletis’ AISBDD and ULAP technologies enable the Company to design, optimize and develop multiple once-monthly SQ ultra-long-acting peptides, including ASC35 and ASC36. Based on the properties of peptides, the Company can design, through its proprietary ULAP technology, various slow-release constants (k) for peptides in SQ depots to precisely release injected peptides over desired dosing intervals to reduce peak-to-trough ratios and improve clinical outcomes.
Conference Call
Ascletis will host a conference call in Mandarin at 10:00 a.m. China Standard Time on November 13, 2025. A live webcast of the call will be available via Tencent Meeting/ VooV Meeting, with the Meeting ID: 573-120-481, or access links of:
Chinese Mainland: https://meeting.tencent.com/dm/uIyhG5Mtu3op; or
International: https://voovmeeting.com/dm/uIyhG5Mtu3op.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
For more information, please visit www.ascletis.com.
Contact：
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
[email protected]Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
[email protected]
[email protected]SOURCE Ascletis Pharma Inc.
Continue Reading
-
High blood pressure rates in children nearly doubled in 20 years, global review finds | Children
The rate of children and teenagers living with high blood pressure globally has nearly doubled because of a toxic combination of unhealthy diets, mass inactivity and soaring levels of obesity, according to the largest review of its kind.
Experts…
Continue Reading
-
US Stock Futures Edge Lower, Oil Extends Losses: Markets Wrap
(Bloomberg) — US equity-index futures edged lower and Asian markets opened on a subdued note after a lackluster Wall Street session, as investors stayed cautious with limited economic data clouding the outlook for Federal Reserve policy.
Contracts for the S&P 500 and the Nasdaq 100 index retreated 0.2%, after the underlying gauges were largely unchanged Wednesday. However, Bloomberg’s gauge for the Magnificent Seven fell 1.2%, extending declines for a second straight session. Treasuries steadied in early trading Thursday after yields fell across the curve.
The moves were more pronounced in the commodities market as gold and copper advanced on Fed rate-cut bets. Oil extended its drop after slumping by the most since June as a key market gauge flashed weakness and OPEC said global crude supplies surpassed demand sooner than anticipated.
Investor focus is on the yen after Japanese Finance Minister Satsuki Katayama issued a fresh warning on currency movements. The yen weakened to the key threshold of 155 per dollar on Wednesday, inching closer to levels where authorities last intervened in markets.
With US earnings season nearing completion, markets are shifting focus to the Fed and the outlook for potential interest-rate cuts. The absence of key indicators — such as unemployment figures and October’s consumer price index — has fueled uncertainty around monetary policy, with the White House confirming those reports are unlikely to be released due to the shutdown.
“While the markets are pricing the end of the government shutdown, there is an even bigger mountain ahead of us, and that is the resumption of all of the economic data that we have missed,” said Michael Landsberg at Landsberg Bennett Private Wealth Management. “As the fog lifts, we will see if market positioning has been correct and it is still clear sailing or if there is a big repricing necessary.”
The S&P 500 edged up 0.1%, lifted in part by a 9% surge in Advanced Micro Devices Inc. shares. The Nvidia Corp. rival in AI chips projected accelerating sales growth over the next five years, fueled by robust demand for its data center products. Meanwhile, the tech-heavy Nasdaq 100 slipped 0.1%, paring an earlier decline of 0.6%.
There is “probably some profit taking after strong gains on Monday and ahead of Nvidia earnings next week, especially since recent tech earnings have not been enough to satisfy the bulls,” said Sameer Samana, head of global equities and real assets at Wells Fargo Investment Institute. “Also, there’s probably an element of ‘selling the news’ of the shutdown ending.”
Investors are also paying attention to the progress in ending the longest ever US government shutdown.
House Speaker Mike Johnson said he believes the legislation, a hard-fought compromise forged in the Senate and blessed by President Donald Trump, will pass quickly. But he’ll have to keep his fractious party in line in the face of stiff opposition from House Democrats whose leaders are urging them to vote against the legislation.
With the government shutdown delaying key economic data, the real challenge isn’t the short-term drag on growth — it’s the increasing difficulty for investors and the Fed to gauge the economic outlook, noted Seema Shah at Principal Asset Management.
“As data releases resume, the case for a Fed rate cut in December should re-emerge, reinforcing a risk-on backdrop,” she said. “This environment favors US equities, particularly big tech and cyclicals poised to benefit from a more accommodative Fed stance.”
Still, Boston Fed President Susan Collins said she favored holding rates steady amid still-strong growth that could slow or stall progress on cooling inflation.
Treasuries rallied Wednesday, with the 10-year yield closing five basis points lower at 4.07%, fueled by expectations the Fed will cut interest rates in December. Bond traders were also piling into Treasury options, targeting a drop in the 10-year yield below 4% in coming weeks.
Corporate News:
Cisco Systems Inc. shares gained in late trading after the network-equipment giant boosted its 2026 forecast, showing progress in its effort to capture more artificial intelligence spending. Toyota Motor Corp. confirmed it will plow as much as $10 billion into the US over the next five years to boost its local operations. Anthropic PBC plans to spend $50 billion to build custom data centers for artificial intelligence work in several US locations, including Texas and New York, the latest expensive pledge for infrastructure to support the AI boom. Volkswagen AG and Rivian Automotive Inc. have ambitions of selling the electric vehicle technology they’re developing together to other carmakers in the future. Some of the main moves in markets:
Stocks
S&P 500 futures fell 0.1% as of 9:26 a.m. Tokyo time Hang Seng futures fell 0.3% Japan’s Topix rose 0.6% Australia’s S&P/ASX 200 fell 0.2% Euro Stoxx 50 futures rose 0.1% Currencies
The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1589 The Japanese yen was little changed at 154.77 per dollar The offshore yuan was little changed at 7.1116 per dollar The Australian dollar was little changed at $0.6535 Cryptocurrencies
Bitcoin fell 0.4% to $101,494.07 Ether fell 0.5% to $3,406.57 Bonds
The yield on 10-year Treasuries advanced one basis point to 4.08% Japan’s 10-year yield was unchanged at 1.685% Australia’s 10-year yield declined one basis point to 4.37% Commodities
West Texas Intermediate crude fell 0.3% to $58.31 a barrel Spot gold was little changed This story was produced with the assistance of Bloomberg Automation.
©2025 Bloomberg L.P.
Continue Reading